A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 301–400 of 1,003
Bauer, J., Köhler, N., Maringer, Y., Bucher, P., Bilich, T., Zwick, M., Dicks, S., Nelde, A., Dubbelaar, M. L., Scheid, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33746-3 · Cited by 82
Choudhury, N. J., Kiyotani, K., Yap, K. L., Campanile, A., Antic, T., Yew, P. Y., Steinberg, G. D., Park, J. H., Nakamura, Y., & O’Donnell, P. H. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.09.007 · Cited by 82
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer
Lei, Y. L., Xie, Y., Tan, Y. S., Prince, M. E., Moyer, J. S., Nor, J. E., & Wolf, G. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.003 · Cited by 82
Dendritic Cell-Based Immunotherapy in Lung Cancer
Stevens, D., Ingels, J., Lint, S. V., Vandekerckhove, B., & Vermaelen, K. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620374 · Cited by 81
Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity
Zhou, C., Ma, L., Xu, H., Huo, Y., & Luo, J. (2022) · Cell Research · doi:10.1038/s41422-022-00639-5 · Cited by 82
Personalized cancer vaccines: Targeting the cancer mutanome
Zhang, X., Sharma, P. K., Peter Goedegebuure, S., & Gillanders, W. E. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.05.073 · Cited by 70
Neoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 80
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 80
Memory-like Differentiation Enhances NK Cell Responses to Melanoma
Marín, N. D., Krasnick, B. A., Becker‐Hapak, M., Conant, L., Goedegebuure, S. P., Berrien-Elliott, M. M., Robbins, K. J., Foltz, J. A., Foster, M., Wong, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0851 · Cited by 80
Self-citationLi, F., Deng, L., Jackson, K. R., Talukder, A. H., Katailiha, A. S., Bradley, S. D., Zou, Q., Chen, C., Huo, C., Chiu, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002531 · Cited by 80
Charles, J., Chaperot, L., Hannani, D., Costa, J. B., Templier, I., Trabelsi, S., Gil, H., Moisan, A., Persoons, V., Hegelhofer, H., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738812 · Cited by 80
Hao, W., Cui, Y., Fan, Y., Chen, M., Yang, G., Wang, Y., Yang, M., Li, Z., Gong, W., Yang, Y., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01110-0 · Cited by 79
Neoantigen cancer vaccines: a new star on the horizon
Li, X., You, J., Hong, L., Liu, W., Guo, P., & Hao, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0395 · Cited by 79
Bassani-Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C., Stevenson, B. J., Thierry, A.-C., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 74
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 78
Johanns, T. M., Miller, C. A., Liu, C. J., Perrin, R. J., Bender, D. E., Kobayashi, D. K., Campian, J. L., Chicoine, M. R., Dacey, R. G., Huang, J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1561106 · Cited by 78
Self-citationExpression of inducible factors reprograms CAR-T cells for enhanced function and safety
Smole, A., Benton, A., Poussin, M., Eiva, M. A., Mezzanotte, C., Camisa, B., Greco, B. M., Sharma, P., Minutolo, N. G., Gray, F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.006 · Cited by 77
Self-citationCorrelates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 77
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 76
Recent advances and future of immunotherapy for glioblastoma
Kamran, N., Calinescu, A., Candolfi, M., Chandran, M., Mineharu, Y., Asad, A. S., Koschmann, C. J., Núñez, F. J., Lowenstein, P. R., & Castro, M. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1212012 · Cited by 74
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 76
Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
Holl, E. K., Frazier, V., Landa, K., Beasley, G. M., Hwang, E. S., & Nair, S. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01767 · Cited by 74
Li, L., Zhang, X., Wang, X., Kim, S. W., Herndon, J. M., Becker‐Hapak, M., Carreno, B. M., Myers, N. B., Sturmoski, M., McLellan, M. D., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00872-4 · Cited by 74
Self-citationEmerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 74
Mørk, S. K., Kadivar, M., Bol, K. F., Draghi, A., Westergaard, M. C. W., Skadborg, S. K., Overgaard, N. H., Sørensen, A. B., Rasmussen, I. S., Andreasen, L. V., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2023255 · Cited by 74
Ingels, J., Cock, L. D., Stevens, D., Mayer, R. L., Théry, F., Sanchez, G. S., Vermijlen, D., Weening, K., Smet, S. D., Lootens, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101516 · Cited by 76
TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection
Zhou, Z. M., Lyu, X., Wu, J., Yang, X., Wu, S., Zhou, J., Gu, X., Su, Z., & Chen, S. (2017) · Royal Society Open Science · doi:10.1098/rsos.170050 · Cited by 74
Zhu, M., Ding, X., Zhao, R., Liu, X., Shen, H., Cai, C., Ferrari, M., Wang, H. Y., & Wang, R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.004 · Cited by 74
Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens
Bassani‐Sternberg, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7537-2_14 · Cited by 75
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 73
Nejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0599 · Cited by 73
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Ott, P. A., & Wu, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1357 · Cited by 72
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1
Ferris, S. T., Ohara, R. A., Ou, F., Wu, R., Huang, X., Kim, S. K., Chen, J., Liu, T., Schreiber, R. D., Murphy, T. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0865 · Cited by 72
Rajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
The future of cancer immunotherapy: DNA vaccines leading the way
Pandya, A., Shah, Y., Kothari, N., Postwala, H., Shah, A., Parekh, P., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02060-3 · Cited by 71
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Takazawa, M., Ohara, O., et al. (2016) · Cancer Science · doi:10.1111/cas.13131 · Cited by 71
Wan, S., Zhang, B., Li, S., He, B., & Pu, Y. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00434k · Cited by 71
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
Lu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q., Sun, S., Guo, X., Yin, H., Wei, Y., Liu, J. O., et al. (2021) · Hepatology · doi:10.1002/hep.31279 · Cited by 70
The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K.-D., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 62
The Future of Blood Testing Is the Immunome
Arnaout, R., Prak, E. T. L., Schwab, N., Rubelt, F., & Community, T. A. I. R. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626793 · Cited by 72
Chu, Y., Qian, L., Ke, Y., Feng, X., Chen, X., Liu, F., Yu, L., Zhang, L., Tao, Y., Xu, R. C., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01397-7 · Cited by 70
Mutanome directed cancer immunotherapy
Vormehr, M., Diken, M., Boegel, S., Kreiter, S., Türeci, Ÿ., & Şahin, U. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.001 · Cited by 70
Breast Cancer Immunology and Immunotherapy
de la Cruz‐Merino, L., Chiesa, M., Caballero, R., Rojo, F., Carrión, N. P., Carrasco, F. H., & Sánchez‐Margalet, V. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.008 · Cited by 71
Dendritic Cell Vaccines in Ovarian Cancer
Zhang, X., He, T., Li, Y., Chen, L., Liu, H., Wu, Y., & Guo, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613773 · Cited by 70
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69
Melanoma and Vitiligo: In Good Company
Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G., & D’Atri, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225731 · Cited by 69
Lu, Y., Zheng, Z., Lowery, F. J., Gartner, J. J., Prickett, T. D., Robbins, P. F., & Rosenberg, S. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002595 · Cited by 69
Sources of Cancer Neoantigens beyond Single-Nucleotide Variants
Capietto, A.-H., Hoshyar, R., & Delamarre, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710131 · Cited by 69
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
Yu, Y.-R., & Ho, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13293 · Cited by 69
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 68
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Sarivalasis, A., Boudousquié, C., Balint, K., Stevenson, B. J., Gannon, P. O., Iancu, E. M., Rossier, L., Lluesma, S. M., Mathevet, P., Sempoux, C. L., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02133-w · Cited by 68
The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67
Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 67
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 67
Self-citationCancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 67
Chae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 67
Yan, J., Zhang, Z., Zhan, X., Chen, K., Pu, Y., Liang, Y., & He, B. (2021) · Nanoscale · doi:10.1039/d1nr01155c · Cited by 67
ScanNeo: identifying indel-derived neoantigens using RNA-Seq data
Wang, T.-Y., Wang, L., Alam, S. K., Hoeppner, L. H., & Yang, R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz193 · Cited by 66
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 66
Becker, J. P., & Riemer, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883989 · Cited by 66
Meng, M., Wu, J., Feng, Y., Lin, L., Chen, J., Pang, X., Li, Y., Hao, K., Tian, H., & Chen, X. (2024) · Advanced Materials · doi:10.1002/adma.202314309 · Cited by 66
Personalized approaches to active immunotherapy in cancer
Ophir, E., Bobisse, S., Coukos, G., Harari, A., & Kandalaft, L. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.07.004 · Cited by 66
Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses
Seyfizadeh, N., Muthuswamy, R., Mitchell, D. A., Nierkens, S., & Seyfizadeh, N. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.09.002 · Cited by 66
Characterizing neoantigens for personalized cancer immunotherapy
Capietto, A.-H., Jhunjhunwala, S., & Delamarre, L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.007 · Cited by 65
Laurell, A., Lönnemark, M., Brekkan, E., Magnusson, A., Tolf, A., Wallgren, A. C., Andersson, B. A., Adamson, L., Kiessling, R. W., & Karlsson‐Parra, A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0255-0 · Cited by 65
Yu, L., Feng, R., Zhu, L., Hao, Q., Chu, J., Gu, Y., Luo, Y., Zhang, Z., Chen, G., & Chen, H. (2020) · Science Advances · doi:10.1126/sciadv.abb6595 · Cited by 65
Emerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 65
Supabphol, S., Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896702 · Cited by 64
Heras‐Murillo, I., Mañanes, D., Munné, P., Núñez, V., Herrera, J., Català-Montoro, M., Álvarez, M., del Pozo, M. Á., Melero, I., Wculek, S. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58289-1 · Cited by 64
Huber, F., & Bassani‐Sternberg, M. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01208-8 · Cited by 64
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Kiyotani, K., Chan, T., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13498 · Cited by 64
Personalized cancer neoantigen vaccines come of age
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018) · Theranostics · doi:10.7150/thno.24387 · Cited by 64
Rodríguez, J., Álvarez, E. C., Perez‐Gracia, J. L., Rodríguez, I., Viúdez, A., Alfaro, C., Oñate, C., Pérez, G., Rotellar, F., Inogés, S., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0405-z · Cited by 64
Accounting for proximal variants improves neoantigen prediction
Hundal, J., Kiwala, S., Feng, Y.-Y., Liu, C. J., Govindan, R., Chapman, W. C., Uppaluri, R., Swamidass, S. J., Griffith, O. L., Mardis, E. R., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0283-9 · Cited by 64
Self-citationCalmeiro, J., Carrascal, M. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0716-8 · Cited by 64
Nejo, T., Yamamichi, A., Almeida, N. D., Goretsky, Y. E., & Okada, H. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101385 · Cited by 64
Ufer, F., Vargas, P., Engler, J. B., Tintelnot, J., Schattling, B., Winkler, H., Bauer, S., Kursawe, N., Willing, A., Keminer, O., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8665 · Cited by 63
Tumor Cell-Based Vaccine: An Effective Strategy for Eradication of Cancer Cells
Sadeghi, S. A., Bolhassani, A., & Aghasadeghi, M. R. (2022) · Immunotherapy · doi:10.2217/imt-2022-0036 · Cited by 63
Dendritic Cell Therapies for Hematologic Malignancies
Weinstock, M., Rosenblatt, J. M., & Avigan, D. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.004 · Cited by 63
Zhang, X., Qi, Y., Zhang, Q., & Liu, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109542 · Cited by 62
Linette, G. P., Becker-Hapak, M., Skidmore, Z. L., Baroja, M. L., Xu, C., Hundal, J., Spencer, D. H., Fu, W., Cummins, C., Robnett, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906026116 · Cited by 62
Self-citationCancer vaccines as enablers of immunotherapy
Khleif, S. N., & Gupta, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02308-2 · Cited by 64
Hartmaier, R. J., Charo, J., Fabrizio, D. A., Goldberg, M. E., Albacker, L. A., Pao, W. J., & Chmielecki, J. (2017) · Genome Medicine · doi:10.1186/s13073-017-0408-2 · Cited by 62
Considerations for personalized neoantigen vaccination in Malignant glioma
Dunn, G. P., Sherpa, N. D., Manyanga, J., & Johanns, T. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114312 · Cited by 61
Vryza, P., Fischer, T., Mistakidi, E., & Zaravinos, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101788 · Cited by 61
Mohsen, M. O., Vogel, M. T., Riether, C., Müller, J., Salatino, S., Ternette, N., Gomes, A. C., Cabral‐Miranda, G., El-Turabi, A., Ruedl, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01015 · Cited by 61
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Kawazu, M., Ueno, T., Saeki, K., Sax, N., Togashi, Y., Kanaseki, T., Chida, K., Kishigami, F., Sato, K., Kojima, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.010 · Cited by 61
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
Rojas-Sepúlveda, D., Tittarelli, A., Gleisner, M. A., Ávalos, I., Pereda, C., Gallegos, I., González, F. E., López, M. N., Butte, J. M., Roa, J. C., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2157-5 · Cited by 60
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
Tondini, E., Arakelian, T., Oosterhuis, K., Camps, M. G. M., van Duikeren, S., Han, W. G. H., Arens, R., Zondag, G. C. M., van Bergen, J., & OSSENDORP, F. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652539 · Cited by 61
Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine
Wei, L., Zhao, Y., Hu, X., & Tang, L. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01174 · Cited by 60
Immune Therapy Opportunities in Ovarian Cancer
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280539 · Cited by 60
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
Weber, D., Ibn-Salem, J., Sorn, P., Suchan, M., Holtsträter, C., Lahrmann, U., Vogler, I., Schmoldt, K., Lang, F., Schrörs, B., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01247-9 · Cited by 59
Kyte, J. A., Aamdal, S., Dueland, S., Sæbøe-Larsen, S., Inderberg, E. M., Madsbu, U. E., Skovlund, E., Gaudernack, G., & Kvalheim, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1232237 · Cited by 59
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 59
Park, J., Talukder, A. H., Lim, S. A., Kim, K., Pan, K., Melendez, B., Bradley, S. D., Jackson, K. R., Khalili, J. S., Wang, J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0051 · Cited by 59
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.